Search research articles
Contact Us
Filters
Showing results (1-10 of 57) with videos related to
Page
of 6
Sort By:
International Urogynecology Journal
|
December 10, 2013
Inaccuracies in the recently published review on mirabegron
Emad Siddiqui
European Urology
|
February 19, 2019
Reply to So-Ryoung Lee, Byoung-Won Park, and Jae Heon Kim's Letter to the Editor re: Christian Gratzke, Rob van Maanen, Christopher Chapple, et al. Long-term Safety and Efficacy of Combined Mirabegron and Solifenacin Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eur Urol 2018;74:501-9
Christian Gratzke, Emad Siddiqui
Expert Review of Clinical Pharmacology
|
December 22, 2016
Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia
Christopher R Chapple, Emad Siddiqui
The Journal of the Royal Society for the Promotion of Health
|
October 21, 2004
Understanding prostate cancer
Emad Siddiqui, Faiz H Mumtaz, James Gelister
The Journal of the Royal Society for the Promotion of Health
|
October 21, 2004
Cancers of the bladder
N Sengupta, Emad Siddiqui, Faiz H Mumtaz
Neurourology and Urodynamics
|
April 18, 2018
A comparison of the treatment recommendations for neurogenic lower urinary tract dysfunction in the national institute for health and care excellence, European Association of Urology and international consultations on incontinence guidelines
Ashley Jaggi, Marcus Drake, Emad Siddiqui, et al.
BJU International
|
March 14, 2012
Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience
Adrian Wagg, Gerhard Compion, Amanda Fahey, et al.
Expert Opinion on Investigational Drugs
|
March 16, 2021
Fezolinetant in the treatment of vasomotor symptoms associated with menopause
Herman Depypere, Christopher Lademacher, Emad Siddiqui, et al.
Advances in Therapy
|
April 23, 2024
Correction to: Psychometric Evaluation of the MENQOL Instrument in Women Experiencing Vasomotor Symptoms Associated with Menopause
Neil M Schultz, Antonia Morga, Emad Siddiqui, et al.
Health and Quality of Life Outcomes
|
November 22, 2023
Psychometric evaluation of the PROMIS SD-SF-8b instrument in individuals experiencing vasomotor symptoms due to menopause
Neil M Schultz, Antonia Morga, Emad Siddiqui, et al.
Page
of 6
Search research articles
Search
Showing results (1-10 of 57) with videos related to
Sort By:
Page
of 6
International Urogynecology Journal
|
December 10, 2013
Inaccuracies in the recently published review on mirabegron
Emad Siddiqui
European Urology
|
February 19, 2019
Reply to So-Ryoung Lee, Byoung-Won Park, and Jae Heon Kim's Letter to the Editor re: Christian Gratzke, Rob van Maanen, Christopher Chapple, et al. Long-term Safety and Efficacy of Combined Mirabegron and Solifenacin Compared with Monotherapy in Patients with Overactive Bladder: A Randomised, Multicentre Phase 3 Study (SYNERGY II). Eur Urol 2018;74:501-9
Christian Gratzke, Emad Siddiqui
Expert Review of Clinical Pharmacology
|
December 22, 2016
Mirabegron for the treatment of overactive bladder: a review of efficacy, safety and tolerability with a focus on male, elderly and antimuscarinic poor-responder populations, and patients with OAB in Asia
Christopher R Chapple, Emad Siddiqui
The Journal of the Royal Society for the Promotion of Health
|
October 21, 2004
Understanding prostate cancer
Emad Siddiqui, Faiz H Mumtaz, James Gelister
The Journal of the Royal Society for the Promotion of Health
|
October 21, 2004
Cancers of the bladder
N Sengupta, Emad Siddiqui, Faiz H Mumtaz
Neurourology and Urodynamics
|
April 18, 2018
A comparison of the treatment recommendations for neurogenic lower urinary tract dysfunction in the national institute for health and care excellence, European Association of Urology and international consultations on incontinence guidelines
Ashley Jaggi, Marcus Drake, Emad Siddiqui, et al.
BJU International
|
March 14, 2012
Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience
Adrian Wagg, Gerhard Compion, Amanda Fahey, et al.
Expert Opinion on Investigational Drugs
|
March 16, 2021
Fezolinetant in the treatment of vasomotor symptoms associated with menopause
Herman Depypere, Christopher Lademacher, Emad Siddiqui, et al.
Advances in Therapy
|
April 23, 2024
Correction to: Psychometric Evaluation of the MENQOL Instrument in Women Experiencing Vasomotor Symptoms Associated with Menopause
Neil M Schultz, Antonia Morga, Emad Siddiqui, et al.
Health and Quality of Life Outcomes
|
November 22, 2023
Psychometric evaluation of the PROMIS SD-SF-8b instrument in individuals experiencing vasomotor symptoms due to menopause
Neil M Schultz, Antonia Morga, Emad Siddiqui, et al.
Page
of 6